{"id":3635,"date":"2026-10-06T09:00:00","date_gmt":"2026-10-06T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3635"},"modified":"2026-10-06T09:00:00","modified_gmt":"2026-10-06T13:00:00","slug":"enable-2-pivotal-cml-design-disclosed","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3635","title":{"rendered":"ENABLE 2 Pivotal CML Design Disclosed"},"content":{"rendered":"

Company<\/strong><\/p>\n

Enliven Therapeutics<\/p>\n

Event Type<\/strong><\/p>\n

Regulatory design alignment (company-reported)<\/p>\n

Modality<\/strong><\/p>\n

Small molecule (ATP-competitive BCR::ABL1 inhibitor)<\/p>\n

Asset<\/strong><\/p>\n

Relcobatinib (ELVN-001)<\/p>\n

Target<\/strong><\/p>\n

BCR::ABL1<\/p>\n

Disease Area<\/strong><\/p>\n

Chronic myeloid leukemia (previously treated)<\/p>\n

Summary<\/h4>\n

Enliven reported FDA alignment on the design of ENABLE-2, a planned randomized Phase 3 trial of relcobatinib in previously treated chronic myeloid leukemia. The event specifies a testable pivotal comparison and endpoint but supplies no new efficacy or safety data and is not a regulatory approval.<\/p>\n

The company plans to randomize approximately 450 adults who have received at least one tyrosine-kinase inhibitor, 1:1 to relcobatinib 80 mg once daily or investigator choice of dasatinib, nilotinib or bosutinib. The primary endpoint is major molecular response at week 24; the key secondary endpoint is major molecular response at week 96.<\/p>\n

Enliven says the design could demonstrate statistical superiority if the molecular-response rate exceeds control by at least 10 percentage points. Trial start before year-end 2026 is company guidance, not a completed enrollment milestone. The FDA alignment is reported by the company; no separate FDA document describing the interaction was available.<\/p>\n

Deep Analysis<\/h4>\n

Relcobatinib is designed as a selective ATP-competitive inhibitor of BCR::ABL1, the fusion kinase driving chronic myeloid leukemia. A head-to-head molecular-response endpoint can test differentiation beyond single-arm historical comparisons. Week-96 response should help judge durability, though longer-term progression, treatment-free remission and toxicity remain important to practice.<\/p>\n

Comparator construction is the central strategic question. Dasatinib, nilotinib and bosutinib are relevant second-generation TKIs, but the specified choice set does not include asciminib, an allosteric BCR::ABL1 inhibitor. Prior TKI exposure, mutation genotype, intolerance versus resistance and selection of comparator could change the apparent effect. Stratification and treatment-switching rules have not been described in this short release. A 10-point design target is a statistical assumption and company assessment of clinical meaning, not an observed treatment effect.<\/p>\n

Interpretation A is that the randomized design will clarify whether a selective ATP-site drug improves early molecular control; regulatory design alignment and a durable secondary endpoint support this path. Interpretation B is that favorable Phase 1 signals may weaken against active treatment or a changing standard of care; heterogeneous 2L+ patients and the omitted asciminib comparator support that concern. Published protocol, registry details, achieved enrollment, 24-week and 96-week results, dose modifications and mutation-specific results would distinguish these interpretations.<\/p>\n

Company and Product Background<\/h4>\n

Chronic myeloid leukemia is driven by the BCR::ABL1 fusion kinase and is often controlled for years by oral TKIs; resistance, intolerance and incomplete molecular responses motivate later-line alternatives. Relcobatinib, formerly ELVN-001, is an investigational ATP-competitive BCR::ABL1 inhibitor. Enliven is a clinical-stage developer; ENABLE-2 is its planned registrational study in previously treated adults.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • Regulatory-design milestone announced 6 October 2026, based on company account of FDA interaction.<\/li>\n
  • Planned ~450-patient, second-line-or-later randomized Phase 3 study.<\/li>\n
  • Primary endpoint: MMR at week 24; key secondary: MMR at week 96.<\/li>\n
  • Comparator choices: dasatinib, nilotinib or bosutinib; asciminib is not listed.<\/li>\n
  • Study initiation before year-end is guidance, not a readout.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    ENABLE-2 converts a CML development hypothesis into a specified randomized test. Its importance lies in the comparator and durable molecular-response design, not an inference that relcobatinib is superior. Protocol-level stratification and eventual head-to-head outcomes will determine whether the design captures a clinically useful advantage.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal Importance: 4 of 5. Signal Direction: neutral. Confidence in Facts: high for the disclosed plan; moderate for the uncorroborated characterization of FDA alignment. Confidence in Interpretation: moderate-low. Missing facts: public protocol, stratification, statistical plan, anticipated comparator mix, mutation subgroups and finalized registry record. Red-team: a design agreement and target effect size do not establish efficacy, safety or approval probability.<\/p>\n","protected":false},"excerpt":{"rendered":"

    Enliven reported FDA alignment on the design of ENABLE-2, a planned randomized Phase 3 trial of relcobatinib in previously treated chronic myeloid leukemia. The event specifies a testable pivotal comparison and endpoint but supplies…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[945,946,944,947,942,943],"class_list":["post-3635","post","type-post","status-publish","format-standard","hentry","category-therapeutic-indication","tag-bcrabl1","tag-chronic-myeloid-leukemia","tag-elvn-001","tag-enable-2","tag-enliven-therapeutics","tag-relcobatinib"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3635","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3635"}],"version-history":[{"count":0,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3635\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3635"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3635"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3635"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}